COMBINATION THERAPY FOR CANCER

The present invention relates to the use of a specific binding molecules which binds human ANXA1 in combination with a second active agent for use in the treatment of cancer. Second active agents include thymidylate synthetase inhibitors, nucleobase analogues, checkpoint inhibitors, proteasome inhib...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	INGHAM, James Alexander, WOOD, Christopher Barry, CRICHTON, Scott James, FABIAN, Charlene, HAYS, Henry Charles Wilson, DEMPSEY, Fiona Carolyn
Format:	Patent
Sprache:	eng
Schlagworte:	CHEMISTRY HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PEPTIDES PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online-Zugang:	Volltext bestellen
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	The present invention relates to the use of a specific binding molecules which binds human ANXA1 in combination with a second active agent for use in the treatment of cancer. Second active agents include thymidylate synthetase inhibitors, nucleobase analogues, checkpoint inhibitors, proteasome inhibitors, taxanes, platinum-based chemotherapy agents and nucleoside analogues. Preferred cancers for treatment are pancreatic cancer, colorectal cancer, breast cancer, lung cancer, myeloma and mantle cell lymphoma. Related kits, products and uses are also provided.